Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis

Nagadenahalli B. Siddappa, Girish Hemashettar, Yin Ling Wong, Samir Lakhashe, Robert A. Rasmussen, Jennifer D. Watkins, Francis J. Novembre, François Villinger, James G. Else, David C. Montefiori, Ruth M. Ruprecht

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background While some recently transmitted HIV clade C (HIV-C) strains exhibited tier 1 neutralization phenotypes, most were tier 2 strains (J Virol 2010; 84:1439). Because induction of neutralizing antibodies (nAbs) through vaccination against tier 2 viruses has proven difficult, we have generated a tier 1, clade C simian-human immunodeficiency virus (SHIV-C) to permit efficacy testing of candidate AIDS vaccines against tier 1 viruses. Methods SHIV-1157ipEL was created by swapping env of a late-stage virus with that of a tier 1, early form. Results After adaptation to rhesus macaques (RM), passaged SHIV-1157ipEL-p replicated vigorously in vitro and in vivo while maintaining R5 tropism. The virus was reproducibly transmissible intrarectally. Phylogenetically, SHIV-1157ipEL-p Env clustered with HIV-C sequences. All RM chronically infected with SHIV-1157ipEL-p developed high nAb titers against autologous as well as heterologous tier 1 strains. Conclusions SHIV-1157ipEL-p was reproducibly transmitted in RM, induced cross-clade nAbs, and represents a tool to evaluate anti-HIV-C nAb responses in primates.

Original languageEnglish (US)
Pages (from-to)120-128
Number of pages9
JournalJournal of medical primatology
Volume40
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
Neutralizing Antibodies
neutralizing antibodies
Macaca mulatta
HIV
Viruses
viruses
testing
AIDS Vaccines
tropisms
Tropism
neutralization
Primates
Vaccination
vaccination
vaccines
Phenotype
phenotype

Keywords

  • Clade C SHIV
  • Neutralization sensitive
  • R5 SHIV
  • Tier 1
  • Vaccine development

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. / Siddappa, Nagadenahalli B.; Hemashettar, Girish; Wong, Yin Ling; Lakhashe, Samir; Rasmussen, Robert A.; Watkins, Jennifer D.; Novembre, Francis J.; Villinger, François; Else, James G.; Montefiori, David C.; Ruprecht, Ruth M.

In: Journal of medical primatology, Vol. 40, No. 2, 01.04.2011, p. 120-128.

Research output: Contribution to journalArticle

Siddappa, NB, Hemashettar, G, Wong, YL, Lakhashe, S, Rasmussen, RA, Watkins, JD, Novembre, FJ, Villinger, F, Else, JG, Montefiori, DC & Ruprecht, RM 2011, 'Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis', Journal of medical primatology, vol. 40, no. 2, pp. 120-128. https://doi.org/10.1111/j.1600-0684.2010.00454.x
Siddappa, Nagadenahalli B. ; Hemashettar, Girish ; Wong, Yin Ling ; Lakhashe, Samir ; Rasmussen, Robert A. ; Watkins, Jennifer D. ; Novembre, Francis J. ; Villinger, François ; Else, James G. ; Montefiori, David C. ; Ruprecht, Ruth M. / Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. In: Journal of medical primatology. 2011 ; Vol. 40, No. 2. pp. 120-128.
@article{f7483e8dcf314490856027777934e616,
title = "Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis",
abstract = "Background While some recently transmitted HIV clade C (HIV-C) strains exhibited tier 1 neutralization phenotypes, most were tier 2 strains (J Virol 2010; 84:1439). Because induction of neutralizing antibodies (nAbs) through vaccination against tier 2 viruses has proven difficult, we have generated a tier 1, clade C simian-human immunodeficiency virus (SHIV-C) to permit efficacy testing of candidate AIDS vaccines against tier 1 viruses. Methods SHIV-1157ipEL was created by swapping env of a late-stage virus with that of a tier 1, early form. Results After adaptation to rhesus macaques (RM), passaged SHIV-1157ipEL-p replicated vigorously in vitro and in vivo while maintaining R5 tropism. The virus was reproducibly transmissible intrarectally. Phylogenetically, SHIV-1157ipEL-p Env clustered with HIV-C sequences. All RM chronically infected with SHIV-1157ipEL-p developed high nAb titers against autologous as well as heterologous tier 1 strains. Conclusions SHIV-1157ipEL-p was reproducibly transmitted in RM, induced cross-clade nAbs, and represents a tool to evaluate anti-HIV-C nAb responses in primates.",
keywords = "Clade C SHIV, Neutralization sensitive, R5 SHIV, Tier 1, Vaccine development",
author = "Siddappa, {Nagadenahalli B.} and Girish Hemashettar and Wong, {Yin Ling} and Samir Lakhashe and Rasmussen, {Robert A.} and Watkins, {Jennifer D.} and Novembre, {Francis J.} and Fran{\cc}ois Villinger and Else, {James G.} and Montefiori, {David C.} and Ruprecht, {Ruth M.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1111/j.1600-0684.2010.00454.x",
language = "English (US)",
volume = "40",
pages = "120--128",
journal = "Journal of Medical Primatology",
issn = "0047-2565",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis

AU - Siddappa, Nagadenahalli B.

AU - Hemashettar, Girish

AU - Wong, Yin Ling

AU - Lakhashe, Samir

AU - Rasmussen, Robert A.

AU - Watkins, Jennifer D.

AU - Novembre, Francis J.

AU - Villinger, François

AU - Else, James G.

AU - Montefiori, David C.

AU - Ruprecht, Ruth M.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background While some recently transmitted HIV clade C (HIV-C) strains exhibited tier 1 neutralization phenotypes, most were tier 2 strains (J Virol 2010; 84:1439). Because induction of neutralizing antibodies (nAbs) through vaccination against tier 2 viruses has proven difficult, we have generated a tier 1, clade C simian-human immunodeficiency virus (SHIV-C) to permit efficacy testing of candidate AIDS vaccines against tier 1 viruses. Methods SHIV-1157ipEL was created by swapping env of a late-stage virus with that of a tier 1, early form. Results After adaptation to rhesus macaques (RM), passaged SHIV-1157ipEL-p replicated vigorously in vitro and in vivo while maintaining R5 tropism. The virus was reproducibly transmissible intrarectally. Phylogenetically, SHIV-1157ipEL-p Env clustered with HIV-C sequences. All RM chronically infected with SHIV-1157ipEL-p developed high nAb titers against autologous as well as heterologous tier 1 strains. Conclusions SHIV-1157ipEL-p was reproducibly transmitted in RM, induced cross-clade nAbs, and represents a tool to evaluate anti-HIV-C nAb responses in primates.

AB - Background While some recently transmitted HIV clade C (HIV-C) strains exhibited tier 1 neutralization phenotypes, most were tier 2 strains (J Virol 2010; 84:1439). Because induction of neutralizing antibodies (nAbs) through vaccination against tier 2 viruses has proven difficult, we have generated a tier 1, clade C simian-human immunodeficiency virus (SHIV-C) to permit efficacy testing of candidate AIDS vaccines against tier 1 viruses. Methods SHIV-1157ipEL was created by swapping env of a late-stage virus with that of a tier 1, early form. Results After adaptation to rhesus macaques (RM), passaged SHIV-1157ipEL-p replicated vigorously in vitro and in vivo while maintaining R5 tropism. The virus was reproducibly transmissible intrarectally. Phylogenetically, SHIV-1157ipEL-p Env clustered with HIV-C sequences. All RM chronically infected with SHIV-1157ipEL-p developed high nAb titers against autologous as well as heterologous tier 1 strains. Conclusions SHIV-1157ipEL-p was reproducibly transmitted in RM, induced cross-clade nAbs, and represents a tool to evaluate anti-HIV-C nAb responses in primates.

KW - Clade C SHIV

KW - Neutralization sensitive

KW - R5 SHIV

KW - Tier 1

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=79952215529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952215529&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0684.2010.00454.x

DO - 10.1111/j.1600-0684.2010.00454.x

M3 - Article

C2 - 21044092

AN - SCOPUS:79952215529

VL - 40

SP - 120

EP - 128

JO - Journal of Medical Primatology

JF - Journal of Medical Primatology

SN - 0047-2565

IS - 2

ER -